Posted by Michael Wonder on 07 Jun 2023
Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory follicular lymphoma
7 June 2023 - NICE has published evidence-based recommendations on the use of axicabtagene ciloleucel (Yescarta) for the treatment of adults with relapsed or refractory follicular lymphoma.
Axicabtagene ciloleucel is not recommended for the treatment of adults with relapsed or refractory follicular lymphoma after three or more systemic treatments.
